Dr. Robson on Breast Cancer Risk Management

Mark E. Robson, MD
Published: Thursday, Aug 25, 2016


Mark E. Robson, MD, Clinic Director, Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, discusses managing breast cancer risk.
 
There are other mutations and genes that can increase breast cancer risk besides BRCA1 and BRCA2. These mutations should be managed differently, said Robson His team has developed a framework to provide oncologists with information about these new genes.
 
Another issue regarding breast cancer risk management surrounds discussing with patients whether or not they need to undergo preventative surgery, such as a mastectomy. This has become more commonly accepted in the United States, said Robson.
 
Preventative surgery may make sense for some women with a high-risk of breast cancer. However, oncologists do need to balance a patient’s desire to have surgery for peace-of-mind with their risk level, said Robson.
 

Mark E. Robson, MD, Clinic Director, Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, discusses managing breast cancer risk.
 
There are other mutations and genes that can increase breast cancer risk besides BRCA1 and BRCA2. These mutations should be managed differently, said Robson His team has developed a framework to provide oncologists with information about these new genes.
 
Another issue regarding breast cancer risk management surrounds discussing with patients whether or not they need to undergo preventative surgery, such as a mastectomy. This has become more commonly accepted in the United States, said Robson.
 
Preventative surgery may make sense for some women with a high-risk of breast cancer. However, oncologists do need to balance a patient’s desire to have surgery for peace-of-mind with their risk level, said Robson.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x